David M Weinstock

US Patent:

20120282258, Nov 8, 2012

Filed:

Nov 24, 2010

Appl. No.:

13/508395

Inventors:

David Weinstock - Jamaica Plain MA, US
Akinori Yoda - Brookline MA, US

Assignee:

DANA-FARBER CANCER INSTITUTE, INC. - Boston MA

International Classification:

C07K 16/30
C12N 15/12
C12N 15/63
C12N 5/10
A61P 35/02
A61K 31/7088
C12Q 1/68
C07K 14/705
A61K 39/395

US Classification:

4241381, 530350, 536 235, 4353201, 5303877, 4241781, 514 44 A, 435 612, 5303917, 435369, 435358, 435325

Abstract:

The invention relates to cytokine receptor-like factor 2 (CRLF2), and particularly certain mutant forms of CRLF2, as prognostic and therapeutic targets in precursor B-cell acute lymphoblastic leukemia (B-ALL). Mutant CRLF2 with a Phe232-Cys (F232C) mutation is overexpressed and constitutively activates STAT5 in a subset of B-ALL patients with particularly poor prognosis. Methods and compositions useful for identifying, inhibiting expression, and inhibiting activity of the mutant CRLF2 are provided. Also provided are methods and compositions useful for treating B-ALL.

US Patent:

20210128557, May 6, 2021

Filed:

Oct 30, 2020

Appl. No.:

17/085650

Inventors:

- Cambridge MA, US
- Boston MA, US
David Weinstock - Boston MA, US
Mark Murakami - Boston MA, US
Scott Manalis - Cambridge MA, US
Andrew Navia - Cambridge MA, US

International Classification:

A61K 31/506
C07K 16/28
A61K 45/06
A61P 35/02
A61K 31/427
A61K 31/5383
A61K 31/44
A61K 31/403

Abstract:

Described in exemplary embodiments herein are methods, compositions, and kits for diagnosing, prognosing, monitoring, treating and/or preventing a hemopoietic malignancy and/or relapse thereof in a subject. In some embodiments, the methods can include determining an average cellular mass of cells in a sample from the subject and/or detecting one or more molecular signatures in one or more of the cells. In some embodiments, treatment includes administering one or more BCR-ABL tyrosine kinase inhibitors or a pharmaceutical formulation thereof, one or more pre-BCR signaling pathway inhibitors or a pharmaceutical formulation thereof, one or more p38 MAPK inhibitors or a pharmaceutical formulation thereof or any combination thereof.

US Patent:

20160194718, Jul 7, 2016

Filed:

May 21, 2014

Appl. No.:

14/890720

Inventors:

- Boston MA, US
David Weinstock - Jamaica Plain MA, US

International Classification:

C12Q 1/68
A61K 31/496
G01N 33/574
A61K 31/55

Abstract:

The present invention relates to methods for identifying, assessing, preventing, and treating cancer (e.g., lymphoid and/or myeloid malignancies such as B-ALL in humans). A variety of histone H3K27rne3 biomarkers are provided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers is associated with cancer status and indicates amenability to treatment or prevention by modulating H3K27me3 levels. The present invention further relates to methods of increasing the number of lymphoid progenitor cells (e.g., increase self-renewal and cell proliferation) by contacting the lymphoid progenitor cells (e.g., wild type and/or genomically altered cells) with an agent that inhibits polycomb repressor complex 2 (PRC2) activity or reduces H3K27roe3 levels.